The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β- mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells

Partha Mukhopadhyay, M. Aktar Ali, Animesh Nandi, Peter Carreon, Hak Choy, Debabrata Saha

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Overexpression of cyclooxygenase-2 (COX-2) is frequently observed in several human cancers, including lung, colon, and head and neck. Malignancies are also associated with the dysregulation of cell cycle events and concomitant elevated activity of cyclin-dependent kinases (CDK). CDK2 is a key cell cycle regulatory protein that controls the transition of cells from G1 to S phase. In this study, we furnish several lines of evidence that show a functional role for the CDK2 in interleukin-1β (IL-1β)-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2 activity. First, we show that BMS-387032, a potent CDK2 inhibitor, blocks IL-1β-induced expression as well as steady-state mRNA levels of COX-2. Second, we show that small interfering RNA that abrogates CDK2 expression also blocks IL-1β-induced COX-2 expression. Third, results from in vitro kinase assays clearly show that IL-1β induces CDK2 activity in H358 cells and this activity is significantly inhibited by BMS-387032. Moreover, CDK2 inhibition blocks IL-1β-induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transcription of the COX-2 gene. We also observed that BMS-387032 does not inhibit endogenous expression of COX-2 or prostaglandin synthesis in lung carcinoma cells. Finally, we provide evidence showing that IL-1β-induced signaling events, such as p38 mitogen-activated protein kinase, phosphorylated stress-activated protein kinase/c-Jun NH 2-terminal kinase, phosphorylated AKT, and phosphorylated extracellular signal-regulated kinase 1/2, are not inhibited by CDK2 inhibitor. Taken together, the data suggest that CDK2 activity may play an important event in the IL-1β-induced COX-2 expression and prostaglandin E2 synthesis and might represent a novel target for BMS-387032.

Original languageEnglish (US)
Pages (from-to)1758-1766
Number of pages9
JournalCancer Research
Volume66
Issue number3
DOIs
StatePublished - Feb 1 2006

Fingerprint

Cyclin-Dependent Kinase 2
Cyclooxygenase 2
Interleukin-1
Down-Regulation
Carcinoma
Lung
Phosphotransferases
CCAAT-Enhancer-Binding Protein-beta
Cell Cycle Proteins
Mitogen-Activated Protein Kinase 3
Cyclin-Dependent Kinases
Mitogen-Activated Protein Kinase 1
p38 Mitogen-Activated Protein Kinases
Heat-Shock Proteins
S Phase
Dinoprostone
Non-Small Cell Lung Carcinoma
Protein Kinases
Small Interfering RNA
Prostaglandins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β- mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells. / Mukhopadhyay, Partha; Ali, M. Aktar; Nandi, Animesh; Carreon, Peter; Choy, Hak; Saha, Debabrata.

In: Cancer Research, Vol. 66, No. 3, 01.02.2006, p. 1758-1766.

Research output: Contribution to journalArticle

@article{2fa3a4ac0dd344fa9e0361b7429e509d,
title = "The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β- mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells",
abstract = "Overexpression of cyclooxygenase-2 (COX-2) is frequently observed in several human cancers, including lung, colon, and head and neck. Malignancies are also associated with the dysregulation of cell cycle events and concomitant elevated activity of cyclin-dependent kinases (CDK). CDK2 is a key cell cycle regulatory protein that controls the transition of cells from G1 to S phase. In this study, we furnish several lines of evidence that show a functional role for the CDK2 in interleukin-1β (IL-1β)-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2 activity. First, we show that BMS-387032, a potent CDK2 inhibitor, blocks IL-1β-induced expression as well as steady-state mRNA levels of COX-2. Second, we show that small interfering RNA that abrogates CDK2 expression also blocks IL-1β-induced COX-2 expression. Third, results from in vitro kinase assays clearly show that IL-1β induces CDK2 activity in H358 cells and this activity is significantly inhibited by BMS-387032. Moreover, CDK2 inhibition blocks IL-1β-induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transcription of the COX-2 gene. We also observed that BMS-387032 does not inhibit endogenous expression of COX-2 or prostaglandin synthesis in lung carcinoma cells. Finally, we provide evidence showing that IL-1β-induced signaling events, such as p38 mitogen-activated protein kinase, phosphorylated stress-activated protein kinase/c-Jun NH 2-terminal kinase, phosphorylated AKT, and phosphorylated extracellular signal-regulated kinase 1/2, are not inhibited by CDK2 inhibitor. Taken together, the data suggest that CDK2 activity may play an important event in the IL-1β-induced COX-2 expression and prostaglandin E2 synthesis and might represent a novel target for BMS-387032.",
author = "Partha Mukhopadhyay and Ali, {M. Aktar} and Animesh Nandi and Peter Carreon and Hak Choy and Debabrata Saha",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-05-3317",
language = "English (US)",
volume = "66",
pages = "1758--1766",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β- mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells

AU - Mukhopadhyay, Partha

AU - Ali, M. Aktar

AU - Nandi, Animesh

AU - Carreon, Peter

AU - Choy, Hak

AU - Saha, Debabrata

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Overexpression of cyclooxygenase-2 (COX-2) is frequently observed in several human cancers, including lung, colon, and head and neck. Malignancies are also associated with the dysregulation of cell cycle events and concomitant elevated activity of cyclin-dependent kinases (CDK). CDK2 is a key cell cycle regulatory protein that controls the transition of cells from G1 to S phase. In this study, we furnish several lines of evidence that show a functional role for the CDK2 in interleukin-1β (IL-1β)-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2 activity. First, we show that BMS-387032, a potent CDK2 inhibitor, blocks IL-1β-induced expression as well as steady-state mRNA levels of COX-2. Second, we show that small interfering RNA that abrogates CDK2 expression also blocks IL-1β-induced COX-2 expression. Third, results from in vitro kinase assays clearly show that IL-1β induces CDK2 activity in H358 cells and this activity is significantly inhibited by BMS-387032. Moreover, CDK2 inhibition blocks IL-1β-induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transcription of the COX-2 gene. We also observed that BMS-387032 does not inhibit endogenous expression of COX-2 or prostaglandin synthesis in lung carcinoma cells. Finally, we provide evidence showing that IL-1β-induced signaling events, such as p38 mitogen-activated protein kinase, phosphorylated stress-activated protein kinase/c-Jun NH 2-terminal kinase, phosphorylated AKT, and phosphorylated extracellular signal-regulated kinase 1/2, are not inhibited by CDK2 inhibitor. Taken together, the data suggest that CDK2 activity may play an important event in the IL-1β-induced COX-2 expression and prostaglandin E2 synthesis and might represent a novel target for BMS-387032.

AB - Overexpression of cyclooxygenase-2 (COX-2) is frequently observed in several human cancers, including lung, colon, and head and neck. Malignancies are also associated with the dysregulation of cell cycle events and concomitant elevated activity of cyclin-dependent kinases (CDK). CDK2 is a key cell cycle regulatory protein that controls the transition of cells from G1 to S phase. In this study, we furnish several lines of evidence that show a functional role for the CDK2 in interleukin-1β (IL-1β)-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2 activity. First, we show that BMS-387032, a potent CDK2 inhibitor, blocks IL-1β-induced expression as well as steady-state mRNA levels of COX-2. Second, we show that small interfering RNA that abrogates CDK2 expression also blocks IL-1β-induced COX-2 expression. Third, results from in vitro kinase assays clearly show that IL-1β induces CDK2 activity in H358 cells and this activity is significantly inhibited by BMS-387032. Moreover, CDK2 inhibition blocks IL-1β-induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transcription of the COX-2 gene. We also observed that BMS-387032 does not inhibit endogenous expression of COX-2 or prostaglandin synthesis in lung carcinoma cells. Finally, we provide evidence showing that IL-1β-induced signaling events, such as p38 mitogen-activated protein kinase, phosphorylated stress-activated protein kinase/c-Jun NH 2-terminal kinase, phosphorylated AKT, and phosphorylated extracellular signal-regulated kinase 1/2, are not inhibited by CDK2 inhibitor. Taken together, the data suggest that CDK2 activity may play an important event in the IL-1β-induced COX-2 expression and prostaglandin E2 synthesis and might represent a novel target for BMS-387032.

UR - http://www.scopus.com/inward/record.url?scp=32944467415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944467415&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3317

DO - 10.1158/0008-5472.CAN-05-3317

M3 - Article

C2 - 16452236

AN - SCOPUS:32944467415

VL - 66

SP - 1758

EP - 1766

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -